Yanyali Ates, Aytug Banu, Horozoglu Fatih, Nohutcu Ahmet F
Department of Ophthalmology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey.
Am J Ophthalmol. 2007 Jul;144(1):124-6. doi: 10.1016/j.ajo.2007.02.048.
To report the visual acuity (VA) and foveal thickness (FT) changes after intravitreal bevacizumab for diabetic macular edema (DME) in previously vitrectomized eyes.
Retrospective, noncomparative, interventional case series.
Medical records of 11 eyes of 10 patients who underwent intravitreal bevacizumab injection for persistent DME were reviewed. This retrospective study included eyes that had persistent DME despite prior pars plana vitrectomy with internal limiting membrane removal at our institution with optical coherence tomography (OCT) assessment of DME. All eyes received three intravitreal injections of bevacizumab 1.25 mg/0.05 ml monthly.
Mean FT was 408 +/- 77 microm at baseline, 453 +/- 97 microm at three months, and 454 +/- 101 microm at six months (P = .172). Mean Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores were 59 +/- 15 (20/80) at baseline, 59 +/- 16 (20/80) at three months, 57 +/- 15 (20/80) at six months (P = .398).
No change in VA and FT was observed in the short-term after intravitreal bevacizumab for DME in previously vitrectomized eyes.
报告玻璃体内注射贝伐单抗治疗既往已行玻璃体切割术的眼的糖尿病性黄斑水肿（DME）后的视力（VA）和黄斑中心凹厚度（FT）变化。
回顾性、非对照、干预性病例系列研究。
回顾了10例患者11只眼接受玻璃体内注射贝伐单抗治疗持续性DME的病历。这项回顾性研究纳入了尽管在本机构先前已行玻璃体视网膜手术联合内界膜剥除术，但仍存在持续性DME且通过光学相干断层扫描（OCT）评估DME的眼。所有眼均每月接受3次玻璃体内注射1.25 mg/0.05 ml贝伐单抗。
基线时平均FT为408±77微米，3个月时为453±97微米，6个月时为454±101微米（P = 0.172）。平均早期糖尿病性视网膜病变研究（ETDRS）字母评分在基线时为59±15（20/80），3个月时为59±16（20/80），6个月时为57±15（20/80）（P = 0.398）。
对于既往已行玻璃体切割术的眼，玻璃体内注射贝伐单抗治疗DME后短期内未观察到VA和FT的变化。
